Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up. / Buron, Mathias Due; Christensen, Jeppe Romme; Pontieri, Luigi; Joensen, Hanna; Kant, Matthias; Rasmussen, Peter Vestergaard; Sellebjerg, Finn; Sørensen, Per Soelberg; Bech, Danny; Magyari, Melinda.
I: Multiple Sclerosis and Related Disorders, Bind 74, 104713, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up
AU - Buron, Mathias Due
AU - Christensen, Jeppe Romme
AU - Pontieri, Luigi
AU - Joensen, Hanna
AU - Kant, Matthias
AU - Rasmussen, Peter Vestergaard
AU - Sellebjerg, Finn
AU - Sørensen, Per Soelberg
AU - Bech, Danny
AU - Magyari, Melinda
N1 - Publisher Copyright: © 2023 The Author(s)
PY - 2023
Y1 - 2023
N2 - Background: Natalizumab is a widely used high-efficacy treatment in multiple sclerosis (MS). Real-world evidence regarding long-term effectiveness and safety is warranted. We performed a nationwide study evaluating prescription patterns, effectiveness, and adverse events. Methods: A nationwide cohort study using the Danish MS Registry. Patients initiating natalizumab between June 2006 and April 2020 were included. Patient characteristics, annualized relapse rates (ARRs), confirmed Expanded Disability Status Scale (EDSS) score worsening, MRI activity (new/enlarging T2- or gadolinium-enhancing lesions), and reported adverse events were evaluated. Further, prescription patterns and outcomes across different time periods (“epochs”) were analysed. Results: In total, 2424 patients were enrolled, with a median follow-up time of 2.7 years (interquartile range (IQR) 1.2–5.1). In recent epochs, patients were younger, had lower EDSS scores, had fewer pre-treatment relapses and were more often treatment naïve. At 13 years of follow-up, 36% had a confirmed EDSS worsening. On-treatment ARR was 0.30, corresponding to a 72% reduction from pre-initiation. MRI activity was rare, 6.8% had activity within 2–14 months from treatment start, 3.4% within 14–26 months, and 2.7% within 26–38 months. Approximately 14% of patients reported adverse events, with cephalalgia constituting the majority. During the study, 62.3% discontinued treatment. Of these, the main cause (41%) was due to JCV antibodies, while discontinuations due to disease activity (9%) or adverse events (9%) were less frequent. Conclusion: Natalizumab is increasingly used earlier in the disease course. Most patients treated with natalizumab are clinically stable with few adverse events. JCV antibodies constitute the main cause for discontinuation.
AB - Background: Natalizumab is a widely used high-efficacy treatment in multiple sclerosis (MS). Real-world evidence regarding long-term effectiveness and safety is warranted. We performed a nationwide study evaluating prescription patterns, effectiveness, and adverse events. Methods: A nationwide cohort study using the Danish MS Registry. Patients initiating natalizumab between June 2006 and April 2020 were included. Patient characteristics, annualized relapse rates (ARRs), confirmed Expanded Disability Status Scale (EDSS) score worsening, MRI activity (new/enlarging T2- or gadolinium-enhancing lesions), and reported adverse events were evaluated. Further, prescription patterns and outcomes across different time periods (“epochs”) were analysed. Results: In total, 2424 patients were enrolled, with a median follow-up time of 2.7 years (interquartile range (IQR) 1.2–5.1). In recent epochs, patients were younger, had lower EDSS scores, had fewer pre-treatment relapses and were more often treatment naïve. At 13 years of follow-up, 36% had a confirmed EDSS worsening. On-treatment ARR was 0.30, corresponding to a 72% reduction from pre-initiation. MRI activity was rare, 6.8% had activity within 2–14 months from treatment start, 3.4% within 14–26 months, and 2.7% within 26–38 months. Approximately 14% of patients reported adverse events, with cephalalgia constituting the majority. During the study, 62.3% discontinued treatment. Of these, the main cause (41%) was due to JCV antibodies, while discontinuations due to disease activity (9%) or adverse events (9%) were less frequent. Conclusion: Natalizumab is increasingly used earlier in the disease course. Most patients treated with natalizumab are clinically stable with few adverse events. JCV antibodies constitute the main cause for discontinuation.
KW - Multiple sclerosis
KW - Natalizumab
KW - Observational study
KW - Treatment
KW - Treatment outcome
U2 - 10.1016/j.msard.2023.104713
DO - 10.1016/j.msard.2023.104713
M3 - Journal article
C2 - 37058764
AN - SCOPUS:85152124866
VL - 74
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
SN - 2211-0348
M1 - 104713
ER -
ID: 366765886